Funding from the European Union will be available for research involving human embryonic stem cells for at least the next seven years, under an agreement reached in Brussels this week. The decision was taken only after the European Commission gave a firm guarantee that “projects which include research activities which destroy human embryos, including for the procurement of stem cells,” would not be eligible for EU funding. The commission’s statement continued: “The exclusion of funding of this step of research will not prevent [European] Community funding of subsequent steps involving human embryonic stem cells.” The two sentence declaration does not change existing policy. The EU already refuses to fund activities where embryos would be destroyed. It is currently financing nine projects involving embryonic stem cell projects, all of which would satisfy the rules of the new multi-annual European research framework programme, which will come into force in January. Janez Potoenik, the EU’s commissioner for research and one of the main architects of the agreement, noted: “We clarified what we are doing and committed ourselves to continue in that direction in future.” The pledge was sufficient to satisfy Germany, Italy, and Luxembourg, which had originally opposed the funding deal. Other opponents—Poland, Austria, Slovakia, Lithuania, and Malta—stood their ground but did not have enough votes at the Brussels meeting of EU science ministers to block the agreement. The legislation lists three other areas that will not qualify for EU funding: research aimed at human cloning for reproductive purposes, research intended to modify the genetic heritage of human beings, and research to create human embryos solely for the purpose of research. The agreement, which must now be formally approved by the European parliament after its summer recess, will not change the status of stem cell research in Europe. Under the principle of ethical subsidiarity it is up to each individual government, not the EU, to determine whether such research may or may not take place in each country. In Ireland such research is banned and will remain so, but its representative, Micheal Martin, endorsed the agreement. “We have to face up to the challenges of contemporary science, and we have to respect the rights of other member states. It is a delicate but workable compromise between different viewpoints,” he said. David Sainsbury, Britain’s science minister, also welcomed the deal, describing it as “symbolically very significant.” He said that it may increase the number of disillusioned scientists in the field of regenerative medicine leaving the United States for Europe. The amount of EU money expected to be available for stem cell experimentation between 2007 and 2013 is likely to be €50m (£34m; $63m), out of a total research budget €54bn. Each application for an EU grant will have to be individually approved by national representatives.